KR20120067336A - 1회당 100～200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제 - Google Patents

1회당 100～200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제 Download PDF

Info

Publication number
KR20120067336A
KR20120067336A KR1020127005972A KR20127005972A KR20120067336A KR 20120067336 A KR20120067336 A KR 20120067336A KR 1020127005972 A KR1020127005972 A KR 1020127005972A KR 20127005972 A KR20127005972 A KR 20127005972A KR 20120067336 A KR20120067336 A KR 20120067336A
Authority
KR
South Korea
Prior art keywords
osteoporosis
agent
pth
fracture
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127005972A
Other languages
English (en)
Korean (ko)
Inventor
신이치로 시라에
야스오 나카무라
유이코 마스나가
요시히데 노자키
노부유키 고바야시
다츠히코 구로다
히로키 가토
마사시 세라다
가즈요시 호리
Original Assignee
아사히 가세이 파마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120067336(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아사히 가세이 파마 가부시키가이샤 filed Critical 아사히 가세이 파마 가부시키가이샤
Publication of KR20120067336A publication Critical patent/KR20120067336A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127005972A 2009-09-09 2010-09-08 1회당 100～200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제 Ceased KR20120067336A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPJP-P-2009-208039 2009-09-09
JP2009208039 2009-09-09

Related Child Applications (4)

Application Number Title Priority Date Filing Date
KR1020177019823A Division KR20170089017A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR20157003153A Division KR20150021590A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR20147029471A Division KR20140130754A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020177019824A Division KR20170089018A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제

Publications (1)

Publication Number Publication Date
KR20120067336A true KR20120067336A (ko) 2012-06-25

Family

ID=43732444

Family Applications (8)

Application Number Title Priority Date Filing Date
KR1020127005972A Ceased KR20120067336A (ko) 2009-09-09 2010-09-08 1회당 100～200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020207027785A Active KR102335703B1 (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR20147029471A Withdrawn KR20140130754A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020177019823A Ceased KR20170089017A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020177019824A Ceased KR20170089018A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020217009475A Active KR102424644B1 (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020197023161A Ceased KR20190095552A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR20157003153A Ceased KR20150021590A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제

Family Applications After (7)

Application Number Title Priority Date Filing Date
KR1020207027785A Active KR102335703B1 (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR20147029471A Withdrawn KR20140130754A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020177019823A Ceased KR20170089017A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020177019824A Ceased KR20170089018A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020217009475A Active KR102424644B1 (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR1020197023161A Ceased KR20190095552A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
KR20157003153A Ceased KR20150021590A (ko) 2009-09-09 2010-09-08 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제

Country Status (16)

Country Link
US (3) US20120252729A1 (enExample)
EP (3) EP2682124B1 (enExample)
JP (13) JPWO2011030774A1 (enExample)
KR (8) KR20120067336A (enExample)
CN (2) CN102470164B (enExample)
AU (1) AU2010293488B2 (enExample)
BR (1) BR112012003511A2 (enExample)
CA (1) CA2772656A1 (enExample)
ES (3) ES2843649T3 (enExample)
IL (1) IL217854A (enExample)
IN (1) IN2012DN00857A (enExample)
MX (1) MX335951B (enExample)
NZ (2) NZ598370A (enExample)
RU (1) RU2564894C2 (enExample)
WO (1) WO2011030774A1 (enExample)
ZA (1) ZA201201720B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616004T3 (es) * 2009-11-18 2017-06-09 Asahi Kasei Pharma Corporation Agente profiláctico y/o agente terapéutico y/o agente supresor de exacerbación para osteortritis de rodilla humana
JP6235219B2 (ja) * 2013-03-21 2017-11-22 旭化成ファーマ株式会社 脊椎椎体間固定術後の骨癒合促進剤
US10394953B2 (en) 2015-07-17 2019-08-27 Facebook, Inc. Meme detection in digital chatter analysis
WO2018144719A1 (en) * 2017-02-01 2018-08-09 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
JP6637220B2 (ja) * 2017-09-22 2020-01-29 旭化成ファーマ株式会社 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
WO2020090174A1 (ja) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505812B2 (ja) 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CA2414966A1 (en) 2000-06-30 2002-01-10 Suntory Limited A pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration containing the component
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
JP4931306B2 (ja) * 2001-09-27 2012-05-16 旭化成ファーマ株式会社 骨形成を安全に促進させる医薬複合剤
JP2007525472A (ja) * 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物
US7632813B2 (en) * 2004-04-26 2009-12-15 Ono Pharmaceutical Co., Ltd. Bone densifying agent characterized by use of cathepsin K inhibitor with PTH
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
JP2006241098A (ja) * 2005-03-04 2006-09-14 Univ Kurume 骨量減少症の予防または治療薬
EP2311505B1 (en) * 2006-02-09 2013-11-06 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
DE102006043846A1 (de) * 2006-03-14 2007-09-20 Claudia Zours Wirbelsäulenorthesen
CA2680690A1 (en) * 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
CN101274961A (zh) * 2006-03-30 2008-10-01 天津医科大学 重组人甲状旁腺素相关蛋白
CN101125201A (zh) * 2006-08-17 2008-02-20 石家庄欧意药业有限公司 治疗骨质疏松症或防治由于骨质疏松而导致的骨折的药物组合物及其应用
CN101307105B (zh) * 2008-04-28 2012-08-29 中国药科大学 一种能串联表达和同步酸水解释放的人甲状旁腺素1-34肽类似物及其制备方法和应用

Also Published As

Publication number Publication date
KR20210040171A (ko) 2021-04-12
KR20140130754A (ko) 2014-11-11
ZA201201720B (en) 2012-11-28
JP6522715B2 (ja) 2019-05-29
ES2843649T3 (es) 2021-07-20
RU2564894C2 (ru) 2015-10-10
JP6198346B2 (ja) 2017-09-20
KR102335703B1 (ko) 2021-12-07
US20140357560A1 (en) 2014-12-04
ES2662018T3 (es) 2018-04-05
KR20170089018A (ko) 2017-08-02
EP2682124B1 (en) 2018-02-28
KR20170089017A (ko) 2017-08-02
EP2476429A1 (en) 2012-07-18
JP2017105860A (ja) 2017-06-15
CN103893746A (zh) 2014-07-02
JP6043008B2 (ja) 2016-12-14
EP2682125B1 (en) 2020-11-04
RU2012108635A (ru) 2013-10-20
EP2682125A1 (en) 2014-01-08
JP2016130261A (ja) 2016-07-21
JP2019023234A (ja) 2019-02-14
JP2018024710A (ja) 2018-02-15
AU2010293488B2 (en) 2014-11-27
EP2476429A4 (en) 2013-02-27
JP2017105862A (ja) 2017-06-15
BR112012003511A2 (pt) 2019-09-24
JP2017105863A (ja) 2017-06-15
JP2015157854A (ja) 2015-09-03
MX335951B (es) 2016-01-04
EP2682124A1 (en) 2014-01-08
AU2010293488A1 (en) 2012-03-29
WO2011030774A1 (ja) 2011-03-17
CN102470164A (zh) 2012-05-23
KR20190095552A (ko) 2019-08-14
KR20150021590A (ko) 2015-03-02
IL217854A0 (en) 2012-03-29
NZ617397A (en) 2015-02-27
CN102470164B (zh) 2014-04-09
ES2663322T3 (es) 2018-04-12
MX2012002681A (es) 2012-04-19
JPWO2011030774A1 (ja) 2013-02-07
IN2012DN00857A (enExample) 2015-07-10
JP2017105861A (ja) 2017-06-15
JP6274634B2 (ja) 2018-02-07
KR20200115673A (ko) 2020-10-07
NZ598370A (en) 2014-04-30
HK1168284A1 (en) 2012-12-28
JP2017105858A (ja) 2017-06-15
JP6301524B2 (ja) 2018-03-28
JP2017105859A (ja) 2017-06-15
JP2017061511A (ja) 2017-03-30
JP6150846B2 (ja) 2017-06-21
US20140249084A1 (en) 2014-09-04
IL217854A (en) 2016-08-31
JP2015147813A (ja) 2015-08-20
KR102424644B1 (ko) 2022-07-25
CA2772656A1 (en) 2011-03-17
US20120252729A1 (en) 2012-10-04
EP2476429B1 (en) 2018-03-07
JP6275900B2 (ja) 2018-02-07

Similar Documents

Publication Publication Date Title
JP6274634B2 (ja) 骨粗鬆症治療剤ないし予防剤
AU2014218380B2 (en) PTH-containing therapeutic/prophylactic agent for osteoporosis, characterized in that PTH is administered once a week at unit dose of 100 to 200 units
HK1195494A (en) Pth-containing therapeutic/prophylactic agent
HK1168284B (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120306

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120618

Comment text: Request for Examination of Application

PG1501 Laying open of application
AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131027

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140721

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131027

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20141021

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20140721

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20140224

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20130215

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120618

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20141120

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20141021

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20140721

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140224

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20131027

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20130215

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20120618

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150205

PJ0201 Trial against decision of rejection

Patent event date: 20150205

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20141120

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20140721

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20160922

Appeal identifier: 2015101000604

Request date: 20150205

J301 Trial decision

Free format text: TRIAL NUMBER: 2015101000604; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150205

Effective date: 20160922

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20160922

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20150205

Decision date: 20160922

Appeal identifier: 2015101000604

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161019

Patent event code: PE09021S01D

AMND Amendment
PS0601 Decision to reject again after remand of revocation

Patent event date: 20170417

Comment text: Decision to Refuse Application

Patent event code: PS06013S01D

Patent event date: 20161019

Comment text: Notification of reason for refusal

Patent event code: PS06012S01I

Patent event date: 20160922

Comment text: Notice of Trial Decision (Remand of Revocation)

Patent event code: PS06011S01I

Patent event date: 20131027

Comment text: Notification of reason for refusal

Patent event code: PS06012S01I

S601 Decision to reject again after remand of revocation
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170717

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170417

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170216

Comment text: Amendment to Specification, etc.

Patent event code: PX09011S01I

Patent event date: 20141120

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20141021

Comment text: Amendment to Specification, etc.

Patent event code: PX09011S01I

Patent event date: 20140721

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20140224

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20130215

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120618

Comment text: Amendment to Specification, etc.

PS0601 Decision to reject again after remand of revocation

Patent event date: 20170818

Comment text: Decision to Refuse Application

Patent event code: PS06013S01D

Patent event date: 20161019

Comment text: Notification of reason for refusal

Patent event code: PS06012S01I

Patent event date: 20160922

Comment text: Notice of Trial Decision (Remand of Revocation)

Patent event code: PS06011S01I

Patent event date: 20131027

Comment text: Notification of reason for refusal

Patent event code: PS06012S01I

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170818

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170717

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170417

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170216

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20161019

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20141120

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20141021

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20140721

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140224

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20131027

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20130215

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20120618

S601 Decision to reject again after remand of revocation
PJ0201 Trial against decision of rejection

Patent event date: 20171115

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170818

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20170417

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20141120

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20140721

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20180627

Appeal identifier: 2017101005503

Request date: 20171115

J301 Trial decision

Free format text: TRIAL NUMBER: 2017101005503; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20171115

Effective date: 20180627

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20180627

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20171115

Decision date: 20180627

Appeal identifier: 2017101005503

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2018201007057; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20180627

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Patent event date: 20160922

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190822

Appeal identifier: 2018201007057

Request date: 20180827

PJ1302 Judgment (patent court)

Patent event date: 20190823

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20180827

Decision date: 20190822

Appeal identifier: 2018201007057

Appeal kind category: Appeal against decision to decline refusal